Monohydroxy Netupitant, a metabolite of Netupitant, plays a significant role in the field of oncology, particularly in the prevention of chemotherapy-induced nausea and vomiting (CINV). It contributes to the efficacy of antiemetic therapies by enhancing the activity of Netupitant, which is a neurokinin-1 (NK1) receptor antagonist. This metabolite helps in blocking the action of substance P, a neurotransmitter involved in the vomiting reflex, thereby providing better control over nausea and vomiting in patients undergoing chemotherapy. Its presence is crucial for ensuring the prolonged therapeutic effect of Netupitant, making it an essential component in the management of CINV and improving the quality of life for cancer patients.